

- fluorouracil bolus with bimonthly high-dose leucovorin and fluorouracil bolus plus continuous infusion for advanced colorectal cancer: a French intergroup study. *J Clin Oncol* **15**(2): 808-815, 1997.
- 15) Rixe O, Ortuzar W, Alvarez M, *et al*: Oxaliplatin, tetraplatin, cisplatin, and carboplatin: spectrum of activity in drug-resistant cell lines and in the cell lines of the National Cancer Institute's Anticancer Drug Screen panel. *Biochem Pharmacol* **52**(12): 1855-1865, 1996.
- 16) Woynarowski JM, Faivre S, Herzig MC, *et al*: Oxaliplatin-induced damage of cellular DNA. *Mol Pharmacol* **58**(5): 920-927, 2000.
- 17) Schmidt W and Chaney SG: Role of carrier ligand in platinum resistance of human carcinoma cell lines. *Cancer Res* **53**(4): 799-805, 1993.
- 18) Mamenta EL, Poma EE, Kaufmann WK, *et al*: Enhanced replicative bypass of platinum-DNA adducts in cisplatin-resistant human ovarian carcinoma cell lines. *Cancer Res* **54**(13): 3500-3505, 1994.
- 19) Andre T, Bensmaine MA, Louvet C, *et al*: Multicenter phase II study of bimonthly high-dose leucovorin, fluorouracil infusion, and oxaliplatin for metastatic colorectal cancer resistant to the same leucovorin and fluorouracil regimen. *J Clin Oncol* **17**(11): 3560-3568, 1999.
- 20) Rothenberg ML, Oza AM, Bigelow RH, *et al*: Superiority of oxaliplatin and fluorouracil-leucovorin compared with either therapy alone in patients with progressive colorectal cancer after irinotecan and fluorouracil-leucovorin: interim results of a phase III trial. *J Clin Oncol* **21**(11): 2059-2069, 2003.
- 21) Maindrault-Goebel F, de Gramont A, Louvet C, *et al*: High-dose intensity oxaliplatin added to the simplified bimonthly leucovorin and 5-fluorouracil regimen as second-line therapy for metastatic colorectal cancer (FOLFOX 7). *Eur J Cancer* **37**(8): 1000-1005, 2001.